Fertility Test Market

Global Fertility Test Market Size (2023 to 2028)

The global fertility test market size is predicted to value USD 595.6 million in 2023 and USD 879.2 million by 2028, growing at a CAGR of 8.1% CAGR during the forecast period.

The fertility test assesses fertility, and several conditions are linked to it in both men and women. Infertility is a condition of a rational duration of unprotected sex without conception. Couples perform fertility tests to identify the main reason for infertility. The general practitioner or gynecologist first assesses the fertility test results to analyze the specific problem and recommends corrective treatment. Therefore, owing to the increasing demand for fertility testing devices, the global market is expected to increase soon.

MARKET DRIVERS:

The growing incidence of fertility issues both in men and women due to changes in lifestyle and food habits and awareness of the use of fertility monitors at home are propelling the global fertility test market growth.

The decreasing rate of fertility in men and women and the increasing prevalence of first-time pregnancy in women favor the fertility test market growth. In addition, factors such as the increasing population of women affected with PCOS, rising awareness regarding fertility tests among people in developed and developing countries, and the growing adoption rate of technologically advanced ovulation monitors are promoting the market’s growth rate. Furthermore, the rise in demand for remote monitoring and self-testing in young women is a big plus to the market growth. Furthermore, the growing adoption of online pharmacies, increasing availability of cost-friendly fertility kits, and growing focus on initiatives from private and public organizations to develop novel techniques and devices to test fertility rates in men and women are expected to boost the fertility test market growth.

The integration of smart technologies in healthcare, the growing adoption rate of ovulation monitoring devices due to growing awareness among people regarding the benefits of monitoring systems, and the evolution of marketing strategies such as e-commerce sites and social media are further anticipated to result in the growth of the fertility test market.

MARKET RESTRAINTS:

However, issues associated with the accuracy of ovulation prediction kits and urine-based ovulation monitors for women affected by PCOS are major factors hampering the market’s growth rate. In addition, lack of awareness of these kits in rural areas, lack of standardization, and rapid changes in the economic strategies remain further inhibiting the growth of the fertility test market worldwide.

Impact of COVID-19 on the global fertility test market:

The global fertility test market growth was preceding until the spread of COVID-19. The American Society of Reproductive Systems has warned anyone diagnosed with COVID-19 to avoid pregnancy. All the people undergoing fertility treatments like IUI, IVF, and others remain suspended unless and until further instructions. A person undergoing fertility treatment with some reason to suspect COVID-19 symptoms must contact the specialist immediately. During the lockdown period, the government imposed all the necessary guidelines. Patients who were about to undergo fertility tests were canceled and postponed. The social and economic burden caused by the novel coronavirus is becoming the worst issue in the medical sector. During the COVID-19 pandemic, the human reproduction society issued some guidelines for fertility issues during the lockdown period. The virus attacks the target cell by attaching to ACE2, widely expressed in the ovaries, uterus, vagina, and placenta. COVID-19 is likely to interfere the female fertility by regulating ACE2. The ability of the virus to affect the male and female reproductive abilities and whether pregnant women with COVID-19 are at increased risk of fatality or comorbidity. 

REPORT COVERAGE:

This research report on the global fertility test market is segmented and sub-segmented based on testing device, mode of purchase, application, end-user, and region.

Fertility Test Market – By Testing Device:

• Ovulation Predictor Kits
• Fertility Monitors
  • Urine-based Monitors
  • Saliva-based Monitors
  • Other Fertility Monitors
• Male Fertility Testing Products

Based on the testing devices, the ovulation predictor kits segment contributes a significant share of revenues to the global fertility test market. It is anticipated to continue its dominion during the outlook period. The factors boosting the growth of this segment are that ovulation predictor kits are highly efficient and sufficient to control costs, the increasing prevalence of pregnancies in middle-aged women, and the growing demand for OPK kits. 

Fertility Test Market – By Mode of Purchase:

• Non-Prescription/OTC-based
• Prescription-based

Fertility Test Market – By Application:

• Female Fertility Testing
• Male Fertility Testing

Based on the application, the female fertility testing segment is leading the global market. It is anticipated to expand further during the estimated period due to the factors such as the availability of various testing procedures, the increasing prevalence of fertility issues in women, and the expensive nature of IVF testing techniques.

Fertility Test Market – By End User:

• Home care settings
• Hospitals, Fertility Clinics, & Others

Based on end-users, in 2022, the home care settings segment dominated the market and is likely to display significant growth over the forecast period due to the factors such as increasing demand for fertility tests due to the drop-in fertility rate in men and women, increasing demand, and availability of home and remote monitoring options in the market.

Fertility Test Market – By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Regionally, North America held the largest share of the global market in 2022, owing to the rapid adoption of technological developments and the rise in pregnancy-age women. Furthermore, North America is expected to dominate the global fertility testing devices market throughout the forecast period due to several factors, such as declining fertility rate due to an increase in the age of first pregnancy and high incidence of polycystic ovaries syndrome in women of this region. The growing awareness of the benefits provided by fertility awareness methods and ovulation monitors for a successful conception in women.

The Asia Pacific and Europe are anticipated to hold a substantial share of the global market during the forecast period owing to the rise in investments by the government for the development of fertility and ovulation monitors. The growth of the Asia-Pacific is further driven by the increase in the number of women with lifestyle disorders, the growing attention of national and international actors, the increase in costs of setting up ovulation and fertility monitors, and the lowering of the fertility rate.

In Europe, the average fertility rate is 1.8. The lowest fertility rates were recorded in southern Europe, Italy, Spain, and Portugal, ranging between 1.65 and 1.41. China's fertility rates are also falling. In China, the low fertility rate is a bigger problem than the aging population. According to the National Bureau of Statistics, 18.14 million new-born babies were added to the Chinese population last year, a decrease of 645,200 year-on-year, and the birth rate fell from 13.42% in 2018 to 13.17% in 2019. Hence, declining fertility rates and increasing lifestyle disorders among women are expected to drive the market during the forecast period.

KEY MARKET PARTICIPANTS AND SHARE INSIGHTS:

Notable companies leading the global fertility test market profiled in this report are Advacare Pharma, AVA, Babystart, Biozhena, Church & Dwight (US), Fairhaven Health, Fertility Focus, Geratherm Medical, Hilin Life Products, Prestige Brands Holdings (A Part of Gregory Pharmaceutical Holdings) (US), Sensiia, Swiss Precision Diagnostics (SPD) (Switzerland), Taidoc, Uebe Medical and Valley Electronics. New product launches are essential strategies leading companies have adopted to maintain their domination. For Instance, in 2017, NFI Consumer Healthcare acquired the OCT pregnancy test kit developed by Prestige Company. In 2017, Swiss Precision Diagnostics released a Clearblue Connected Ovulation Test System for effective fertility testing. In 2017, Fairhaven Health released a product called TempCue, and the product is used for measuring body temperature.